论文部分内容阅读
为了探讨化疗联合艾迪注射液在术后复发非小细胞肺癌(NSCLC)综合治疗中的应用价值,将40例术后复发NSCLC患者随机分为治疗组与对照组(各20例),治疗组采用NP方案(长春瑞滨+顺铂)联合艾迪注射液;对照组采用单纯NP方案。结果全组40例患者中,无CR病例,治疗组PR 4例,SD 11例,PD 5例;对照组PR 3例,SD 8例,PD 9例。治疗组疾病控制率(CR+PR+SD)75%,对照组55%,两组差异有统计学意义,P<0.05。初步研究结果提示,艾迪注射液联合NP方案治疗,能提高疾病控制率,减少不良反应,改善症状,提高术后复发的NSCLC的生存质量。
In order to investigate the value of chemotherapy combined with Aidi injection in the treatment of postoperative recurrence of non-small cell lung cancer (NSCLC), 40 patients with recurrent NSCLC were randomly divided into treatment group and control group (20 cases each) NP regimen (vinorelbine + cisplatin) combined with Aidi injection; control group with a simple NP program. Results Among the 40 patients, there were no CR cases in the treatment group, 4 cases in the treatment group, 11 cases in the SD group and 5 cases in the PD group. There were 3 cases in the control group, 8 cases in the SD group and 9 cases in the PD group. Treatment group disease control rate (CR + PR + SD) 75%, control group 55%, the difference between the two groups was statistically significant, P <0.05. Preliminary results suggest that Aidi injection combined with NP regimen can improve the disease control rate, reduce adverse reactions, improve symptoms and improve the quality of life of recurrent NSCLC.